Company Encyclopedia
View More
name
IMMUNOTECH-B
06978.HK
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for relapsed and refractory diffuse large B-cell lymphoma; and TCR-T cell series products to treat solid tumors. In addition, the company develops pre-clinical products, such as aT19 to treat hematologic malignancies; YT003 and YT008 for post transplantation infections; YT007 for solid tumors; and VAC-aT19 for hematologic malignancies.
1.377 T
06978.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Immunotech Biopharm Ltd’s Rights Issue Oversubscribed, Raising HK$257.29 Million

    Immunotech Biopharm Ltd has successfully completed its rights issue, raising approximately HK$257.29 million, with net proceeds estimated at HK$251.88 million. The oversubscription reflects strong investor confidence, which may enhance the company's financial position and operational capabilities. Immunotech Biopharm Ltd operates in the biopharmaceutical industry, focusing on innovative healthcare solutions, and has a current market cap of HK$2.03 billion.

    Tip Ranks·
    HK
    06978
    +0.64%
    Tip Ranks·
    HK
    06978
    +0.64%

    IMMUNOTECH-B: Cao Ran appointed as non-executive director

    According to the Zhitong Finance APP, IMMUNOTECH-B announced that starting from October 16, 2025: Mr. Cao Ran has been appointed as a non-executive director and a member of the audit committee; Ms. Yu Xiaohui has resigned as a non-executive director and a member of the audit committee

    Zhitong·
    HK
    06978
    +0.64%
    Zhitong·
    HK
    06978
    +0.64%

    Immunotech Biopharm Ltd. Appoints Cao Ran as Non-Executive Director and Audit Committee Member, Yu Xiaohui Resigns

    Immunotech Biopharm Ltd. has appointed Mr. Cao Ran as a non-executive Director and Audit Committee member, effective October 16, 2025. Ms. Yu Xiaohui has resigned from her roles as non-executive Director and Audit Committee member on the same date due to other job arrangements.

    Reuters·
    HK
    06978
    +0.64%
    Reuters·
    HK
    06978
    +0.64%

    Immunotech Biopharm Ltd files list of directors to HKEX

    Immunotech Biopharm Ltd. has submitted an updated list of directors to the Hong Kong Stock Exchange. The Board is led by Executive Director Mr. Tan Zheng, with Non-executive Directors including Mr. Yang Fan, Mr. Wang Ruihua, Mr. Wang Donghu, Mr. Yang Xin, Mr. Liu Rui, and Mr. Cao Ran. Independent Non-executive Directors are Professor Wang Yingdian, Mr. Ng Chi Kit, Ms. Peng Sujiu, and Mr. Zhang Guoguang. The Board has three committees: Audit, Remuneration, and Nomination, each chaired by different members.

    Reuters·
    HK
    06978
    +0.64%
    Reuters·
    HK
    06978
    +0.64%

    Top Key Executive Zheng Tan, Immunotech Biopharm Ltd's (HKG:6978) largest shareholder sees value of holdings go down 15% after recent drop

    Zheng Tan, the largest shareholder and Top Key Executive of Immunotech Biopharm Ltd (HKG:6978), has seen the value of his holdings decrease by 15% following a recent market drop, resulting in a loss of HK$488 million in market cap. Insiders collectively own 35% of the company, indicating significant potential for both gains and losses. The top four shareholders control over 51% of the company, while institutional ownership remains low, suggesting a lack of interest from larger investors. The general public holds a 25% stake, and private equity firms own 11%.

    Simplywall·
    HK
    06978
    +0.64%
    Simplywall·
    HK
    06978
    +0.64%
    © 2025 Longbridge｜Disclaimer